PPARG and non-small cell lung carcinoma: Treatment of in vitro PTEN-deficient EGFR-mutant NSCLC models with PPARγ agonists (rosiglitazone, pioglitazone) in presence of gefitinib produced a strong synergism and induced PTEN protein expression and autophagy mitigating TKI resistance in NSCLC increasing the anticancer effect.